DIHX
Dihexa
A synthetic analogue of angiotensin IV: N-hexanoyl-tyrosyl-isoleucyl-(6)-aminohexanamide. The hexanoyl and aminohexanoyl groups replace peptide residues at both ends, which is what makes it far more lipophilic than the parent. The published work describes it as acting at hepatocyte growth factor and its receptor c-Met rather than at an angiotensin receptor.
No registered human study names Dihexa as an intervention. ClinicalTrials.gov holds no trial of it, so there is no trial evidence to read — a fact about the public record rather than proof the compound does nothing. No FDA-approved product contains Dihexa. 6 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names Dihexa; the registry search is fuzzy, so every match is re-checked. None of this says whether Dihexa works or is safe.
FDA status
Research only
Human studies
0
Furthest phase
—
Papers, 10 yr
6
Readership
4,044
monthly average, Feb–Jul 2026
Tracking since 2026-07-29 · About this data
What has actually been tested in humans
No registered human study
0
Registered human studies
None
No FDA-approved product contains it
No study of Dihexa in humans is registered on ClinicalTrials.gov. That is a fact about the public record, not a statement that the compound does nothing — but it does mean there is no trial evidence to read, and anyone telling you otherwise should be asked for the registration number. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What Dihexa is, and what it has been studied for
Dihexa is tracked here. Its FDA substance identifier is 9WYX65A5C2.
No registered trial names Dihexa as an intervention, so there is no condition it has been formally studied in. It does have a literature: 6 indexed papers name it in the last ten years. That work is laboratory and animal research, and a paper is not a trial.
Is anyone studying Dihexa?
Papers published each year that name Dihexa in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 0 | 0 | Yes |
| 2018 | 1 | 0 | Yes |
| 2019 | 0 | 0 | Yes |
| 2020 | 0 | 0 | Yes |
| 2021 | 2 | 0 | Yes |
| 2022 | 1 | 0 | Yes |
| 2023 | 0 | 0 | Yes |
| 2024 | 1 | 0 | Yes |
| 2025 | 0 | 0 | Yes |
| 2026 | 1 | 0 | No |
6 papers between 2017 and 2026. A paper counts when “Dihexa” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on Dihexa
6 indexed papers name Dihexa in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
- Hepatocyte growth factor mimetic protects lateral line hair cells from aminoglycoside exposure
- AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway
- The Brain Hepatocyte Growth Factor/c-Met Receptor System: A New Target for the Treatment of Alzheimer's Disease
- The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system
- Dimeric DOTA-alpha-melanocyte-stimulating hormone analogs: synthesis and in vivo characteristics of radiopeptides with high in vitro activity
- Small-Molecule-Directed Hepatocyte-Like Cell Differentiation of Human Pluripotent Stem Cells
- Cognitive benefits of angiotensin IV and angiotensin-(1-7): A systematic review of experimental studies
Collected 2026-08-02from PubMed, phrase-matched on “Dihexa” in title and abstract. Run the same search.
About Dihexa
A synthetic analogue of angiotensin IV: N-hexanoyl-tyrosyl-isoleucyl-(6)-aminohexanamide. The hexanoyl and aminohexanoyl groups replace peptide residues at both ends, which is what makes it far more lipophilic than the parent. The published work describes it as acting at hepatocyte growth factor and its receptor c-Met rather than at an angiotensin receptor.
- Also known as
- N-hexanoic-Tyr-Ile-(6) aminohexanoic amide · PNB-0408
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Reading on this compound
All articles →PepRack articles that reference this compound. This is not a news feed — we syndicate nothing and publish no datelines.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.